SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is trending sharply upward ahead of its highly anticipated earnings report later today, with the community divided between strong bullish sentiment driven by massive AI demand and new product excitement, and cautious predictions of a "sell the news" event following the recent rally.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath is trending amid a significant stock price decline, fueling community debate over broader software sector weakness and perceived threats from AI, contrasted by conviction from investors who highlight strong fundamentals, strategic AI pivots, and upcoming earnings as catalysts for a major rebound and short squeeze.

Circle Internet Group, Inc. is a financial technology company that enables businesses of all sizes to harness the power of digital currencies and public blockchains for payments, commerce and financial applications worldwide. The company was founded by Jeremy J. Allaire and Patrick Sean Neville in August 2013 and is headquartered in New York, NY.

Circle Internet Group Inc. - Ordinary Shares - Class A

Circle

Circle (CRCL) is experiencing a significant surge following a strong Q4 earnings report that exceeded expectations and showcased robust USDC adoption, fueling widespread discussion of a short squeeze and its long-term potential as a core financial infrastructure as stablecoin regulatory clarity is anticipated. However, a divided community also highlights concerns regarding its valuation and sustainability amid the rapid climb.

Navitas Semiconductor Corp. engages in the development of ultra-efficient gallium nitride (GaN) semiconductors. Its GaN power ICs integrate GaN power with drive, control and protection to enable charging, power density, and energy savings for mobile, consumer, enterprise, eMobility and new energy markets. The company was founded by Daniel Kinzer, Nick Fichtenbaum, Gene Sheridan, and Jason Zhang on August 12, 2020 and is headquartered in Torrance, CA.

Navitas Semiconductor Corp

Navitas Semiconductor is trending following its recent earnings, which showed a revenue decline but emphasized a strategic pivot to high-power AI data centers with new GaN and SiC solutions. The community is actively discussing the technology's critical role in addressing AI's escalating energy demands, with significant anticipation for definitive, revenue-generating contracts from hyperscalers like NVIDIA.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is a top discussion point as the community anticipates an imminent ASCO GU data release and digests recent NCCN guideline updates for its ANKTIVA cancer immunotherapy. This comes amidst significant price volatility, which high-conviction longs see as a buying opportunity against a backdrop of heavy short interest, believing ANKTIVA is positioned to become a global standard of care.

Fiserv, Inc. engages in the provision of financial services technology. It operates through the Merchant and Financial segments. The Merchant segment offers commerce-enabling products and services including merchant acquiring and digital commerce and mobile payment services, and security and fraud protection, stored-value, and pay-by-bank solutions to companies of all sizes. The Financial segment provides products and services such as processing of customer loan and deposit accounts, digital payments, and card transactions to financial institutions and corporate and public sector clients. The company was founded by Leslie M. Muma and George D. Dalton on July 31, 1984 and is headquartered in Milwaukee, WI.

Fiserv, Inc.

Fiserv is a hot topic following activist investor Jana Partners' reported stake and mixed Q4 earnings, with community sentiment sharply divided between those who see a "massively undervalued" fintech leader on the cusp of a turnaround and skeptics concerned about sector headwinds and debt. Discussions also center on aggressive call buying and ongoing insider accumulation as signs of potential future upside for the stock.

Cava Group, Inc. is a holding company, which engages in the category-defining Mediterranean fast-casual restaurant brand, bringing together healthful food and bold, satisfying flavors at scale. It operates through the following segments: CAVA and CAVA Foods. The CAVA segment includes the operations of all company-owned CAVA restaurants. The CAVA Foods segment includes the production of dips and spreads used in CAVA restaurants as well as sales from the consumer-packaged goods (CPG) business. The company was founded by Brett Schulman, Ike Grigoropoulus, Dimitri Moshovitis, and Theodore Xenohristos in 2010 and is headquartered in Washington, DC.

Cava Group Inc

CAVA Group Inc

A robust earnings report, featuring beats on revenue and earnings per share, alongside strong same-store sales and ambitious plans for new restaurant openings, is driving significant bullish sentiment for CAVA; the community is actively debating its potential for a short squeeze and sustained growth versus its high valuation compared to peers.

Larimar Therapeutics, Inc. Is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics mitochondrial disorders and Friedreich's ataxia. The company was founded in 2005 and is headquartered in Bala Cynwyd, PA.

Larimar Therapeutics Inc

Larimar Therapeutics is trending after its experimental Friedreich's ataxia treatment received FDA Breakthrough Therapy designation, with the agency open to accelerated approval using a novel biomarker. The community is buzzing with high price targets and buyout speculation, navigating discussions around potential future dilution and the drug's safety profile.

Oddity Tech Ltd. engages in the online retail sale of cosmetics and beauty products. Its products include lipsticks, makeup brushes, mascara, eyelash curlers, and makeup brush cleansers. The company was founded by Oran Holtzman and Shiran Holtzman-Erel on March 23, 2013 and is headquartered in Tel Aviv, Israel.

ODDITY Tech Ltd. - Ordinary Shares - Class A

ODDITY Tech is seeing a surge in conversation following its announcement of a $150 million share buyback program and raised Q2 guidance, which is fueling investor hopes for a short squeeze and a rebound from prior declines linked to an unexpected marketing glitch.

Tempus AI, Inc. is a healthcare technology company, which engages in bringing artificial intelligence and machine learning to healthcare. It focuses on building platforms for oncology, neuropsychiatry, cardiology, infectious disease, and radiology. The company was founded by Eric Paul Lefkofsky in August 2015 and is headquartered in Chicago, IL.

Tempus AI Inc. - Ordinary Shares - Class A

Tempus AI Inc

Tempus AI is trending after its latest earnings revealed impressive revenue growth, particularly in diagnostics, and a record total contract value with pharma partners for its AI-driven oncology platform. However, a wider net loss and anticipated slower revenue growth are sparking a debate among investors, with many seeing a buy-the-dip opportunity fueled by institutional interest and short-squeeze potential.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Cannabis ETF (CNBS) Hits New 52-Week High

CNBS Cannabis ETF climbs to a 52-week high, fueled by rescheduling optimism and potential further gains.

<ul class="summary-bullets"><li>Tilray’s shares, as well as shares of other Cannabis producers, have been surging over the past few days.</li><li>This comes amid reports that President Trump is set to reclassify marijuana, which would result in cannabis companies falling under different tax regulations.</li><li>While awaiting the executive order, retail users on Stocktwits expressed optimism, noting that the TLRY stock could rally even further.</li></ul>Shares of Tilray Brands Inc. (TLRY) have soared nearly 72% over the past five trading sessions as investors await President Donald Trump’s executive order on marijuana reclassification.The New York City-headquartered pharmaceutical company produces and distributes cannabis for medicinal and adult use.Tilray’s shares, as well as shares of other Cannabis producers, have been surging over the past few days amid reports that President Trump is set to reclassify marijuana, which would result in cannabis companies falling under different tax regulations.<a href="https://stocktwits.com/symbol/TLRY">Tilray shares</a> were up nearly 5% in Wednesday’s pre-market trade. Retail sentiment on Stocktwits around the company trended in the ‘extremely bullish’ territory, with the stock being the top trending ticker on the platform at the time of writing.<h2 class="st-heading-2">Retail’s Excited</h2>While awaiting the executive order, retail users on Stocktwits expressed optimism, noting that the TLRY stock could rally even further. One user expects Tilray’s shares to surge past $20 on Wednesday with ease.<stembedurl>https://stocktwits.com/LifeChangingProfits/message/639396013</stembedurl>Another user compared the reclassification of marijuana to a biotech company receiving fast-track approval from the U.S. Food and Drug Administration (FDA) for ten Phase 3 trials simultaneously.<stembedurl>https://stocktwits.com/Hoschton30548/message/639132205</stembedurl>One user expects the TLRY stock to surge past $50 by the end of the year.<stembedurl>https://stocktwits.com/Family2328/message/639372092</stembedurl><h2 class="st-heading-2">Other Cannabis Stocks Surge</h2>Apart from Tilray, expectations of marijuana reclassification have sent other cannabis stocks soaring, too.Canopy Growth Corp. (CGC), an Ontario-based company, saw its shares climb nearly 62% over the past five trading sessions. Aurora Cannabis Inc. (ACB) shares have climbed over 20%, while the Amplify Seymour Cannabis ETF (CNBS) has soared nearly 71% during this period.<h2 class="st-heading-2">Marijuana Reclassification</h2>According to a&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://abcnews.go.com/Politics/trump-sign-executive-order-reclassifying-marijuana-officials/story?id=128472615">report</a> by ABC News citing people familiar with the matter, President Trump is set to sign an executive order on Wednesday that would reclassify marijuana as a Schedule III drug.Under the current Drug Enforcement Administration guidelines, marijuana is listed as a Schedule I drug. The DEA defines Schedule III drugs as having “a moderate to low potential for physical and psychological dependence.”<a href="https://stocktwits.com/symbol/TLRY">TLRY stock</a> is up 5% year-to-date and 16% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/ford-terminates-6-5-billion-battery-deal-lg-energy-after-retreating-from-evs/cLeOWmAREpD">Ford Terminates $6.5 Billion LG Energy Deal After Retreating From EVs — And Retail Is Split</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a Tilray Brands logo is seen displayed on a smartphone and in the background.

TLRY Stock Gained Over 70% In 5 Days, Retail Optimism Spikes Ahead Of Trump's Marijuana Order

The New York City-headquartered pharmaceutical company produces and distributes cannabis for medicinal and adult use.

Equity

6 Top-Performing ETF Areas of Last Week 

Cannabis, metals, space and health care led ETF gains last week. WEED, CNBS, SIL, UFO, GDXJ, PLTM and OZEM outperformed despite tech weakness.

5 Best-Performing Leveraged ETFs of Last Week

Cannabis, space, nat gas & auto led last week's leveraged ETF winners. MSOX, RKLX, KOLD, VOYX and CVNX posted outsized gains despite tech weakness.

Cannabis ETFs Soar Double-Digits on Friday: Here's Why

Cannabis ETFs explode on reform buzz. CNBS, WEED, MSOS and MJ jumped double-digits on Dec. 12, 2025 as Trump reportedly weighs reclassifying marijuana, boosting optimism.

The Zacks Analyst Blog Highlights MSOS, CNBS, WEED, MJ and YOLO

Zacks Analyst Blog highlights MSOS, CNBS, WEED, MJ, and YOLO as marijuana ETFs soar over 100% in three months on U.S. legalization hopes and investor optimism.

From Loss to Lift-Off: Marijuana ETFs Rebound on Legalization Prospects 

Marijuana ETFs, such as WEED, MSOS, and CNBS, are rebounding as hopes for rescheduling boost investor optimism. 

Top-Performing ETF Areas of August That Are Up At Least 20% 

ETFs tied to Cannabis, Asia, China, materials and bitcoin miners led August's gains in Wall Street. ETFs like WEED, KSTR, CNXT, GBUG and WGMI won in August.

Cannabis ETFs Soar as Trump Mulls Over Marijuana Reclassification

Cannabis ETFs like WEED, CNBS and MJ surge after Trump confirmed that his administration is weighing marijuana's move from Schedule I to Schedule III.


Tilray Brands, Inc. faces a regulatory reckoning: regain Nasdaq’s minimum bid price requirements soon or possibly get delisted from the exchange.&nbsp;The retail trading community on Stocktwits believes the cannabis and beer company will soon overcome this hurdle.Leamington, Canada-based Tilray received a non-compliance notice from Nasdaq on Tuesday after its stock failed to maintain the exchange’s $1 minimum closing bid price requirement for 30 consecutive business days.Shares of Tilray have lost more than half their value this year, as cannabis-linked stocks continue to struggle amid stalled federal legalization efforts.The company has 180 calendar days to meet Nasdaq's minimum bid price rule. Its stock must close at or above $1.00 per share for at least 10 consecutive business days before Sept. 21.If the company fails, it may transfer to the Nasdaq Capital Market for another 180-day extension — provided it meets other listing requirements and notifies Nasdaq of its plan to fix the issue, possibly through a reverse stock split.&nbsp;If Nasdaq still determines the company cannot regain compliance, its stock will face delisting.On Stocktwits, sentiment for Tilray ended on a slightly higher ‘bullish’ level on Wednesday amid a 45% jump in message volume.<figure class="image"><img style="aspect-ratio:1318/302;" src="https://news.stocktwits-cdn.com/TLRY_sentiment_and_message_volume_as_of_Macrh_26_png_785b929906.webp" alt="TLRY sentiment and message volume as of Macrh 26.png" width="1318" height="302"><figcaption>TLRY sentiment and message volume as of Macrh 26. | source: Stocktwits</figcaption></figure>One user expressed hopes of Nasdaq being lenient with its process and said there were “zero” delisting fears because, with the extension, Tilray has until April 2026 to regain compliance.<stembedurl>https://stocktwits.com/Finance88/message/609341203</stembedurl>Another user said the company is “vertically scaled to be dominant from flower to drinks to pharma,” pointing to its products being available on the multinational supermarket chain Whole Foods, which is owned by Amazon.com.<stembedurl>https://stocktwits.com/Heb1972/message/609362664</stembedurl>Several retail investors on Stocktwits hope Tilray does not resort to a reverse stock split.<stembedurl>https://stocktwits.com/Rs1015/message/609258289</stembedurl>In January, Tilray’s stock was dealt a blow after the company&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tlry-stock-slides-after-q2-2025-results/chGWAd2RZD">reported</a> disappointing quarterly results and projected a $20 million revenue blow for 2025 from cutting back on certain alcohol beverage brands.Meanwhile, the company said Wednesday that the Massachusetts Superior Court dismissed a lawsuit filed by a shareholder against the company and its subsidiary Hexo.The plaintiff claimed Tilray failed to inform shareholders about Hexo’s corporate actions in late 2022 and its 2023 acquisition, allegedly causing financial losses. He sought nearly $8 million in damages.&nbsp;According to Koyfin data, short interest on Tilray has shot up from 12.7% at the start of the year to 17.3% as of the last week.The stock trades at a significant 180% discount to Wall Street’s average price target of $1.83. Out of 13 analysts covering it, nine rate it ‘hold’ and four ‘buy.’For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the logo of a Canadian pharmaceutical and cannabis company, Tilray, is seen on a smartphone and a PC screen. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)

Tilray Retail Bulls See Nasdaq Compliance On The Horizon, Shareholder Lawsuit Victory Adds Cheer

The company has 180 calendar days to meet Nasdaq's minimum bid price rule. Its stock must close at or above $1.00 per share for at least 10 consecutive business days before Sept. 21.

Amplify ETF Trust - Amplify Seymour Cannabis ETF

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

Ahead of earnings, sentiment is split between blowout AI growth and concerns around macro pressure, positioning, and post-ER volatility. How do you see it playing out?

Current Price	$25.05
Prev Close	$24.47
Open	$24.51
Dividend Yield	N/A
50-Day Moving Average	$27.50
Beta	N/A
Avg. Volume	26,851.75
PE Ratio	N/A

52-Week High	$43.94
52-Week Low	$13.96
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

CNBS
Amplify Seymour Cannabis ETF

Feed

News

Sentiment

Fundamentals

Info

Latest CNBS News

CNBSAmplify Seymour Cannabis ETF